RetinalGenix and Diopsys terminate 2019 Option Exchange Agreement; no options ever issued

RetinalGenix Technologies Inc.

Termination effective Feb 14, 2022; Agreement from Oct 8, 2019 never had conditions satisfied.
No options were issued under the agreement, and the contemplated Exclusive Distribution Agreement was never negotiated.
Both parties are mutually released from any claims related to the Agreement and its termination.
RetinalGenix and Diopsys continue discussions toward a potential Exclusive Distribution Agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.